A detailed history of Entry Point Capital, LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 21,458 shares of ARVN stock, worth $401,908. This represents 0.31% of its overall portfolio holdings.

Number of Shares
21,458
Previous 4,449 382.31%
Holding current value
$401,908
Previous $118 Million 99.55%
% of portfolio
0.31%
Previous 0.17%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$23.66 - $32.73 $402,432 - $556,704
17,009 Added 382.31%
21,458 $528,000
Q2 2024

Aug 13, 2024

BUY
$24.46 - $40.4 $108,822 - $179,739
4,449 New
4,449 $118 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.